Mood stabilizers: Insights from users' perceptions

Opinions and subjective perceptions regarding psychopharmacological treatment have proven to be strong predictors of quality of life, adherence, and general outcomes, as well as a rich source of data for research. Although mood stabilizing agents (MSA) represent the cornerstone of the treatment of bipolar disorders (BDs), data on the experiences of patients undergoing treatment with these drugs are scarce. We aimed to explore and compare user-reported data on four first-line MSA and identify predictors of treatment satisfaction.

We conducted a quantitative analysis of a random sample of 200 posts specifically related to first-line mood stabilizers (lithium, lamotrigine, valproate, and quetiapine) from individuals undergoing long-term treatment for BDs. Demographical, clinical, somatic, and emotional/psychological side-effects and treatment-related data were analyzed.

This study found that the reported levels of satisfaction with MSAs were notably high. Lamotrigine received higher satisfaction ratings than quetiapine and valproate, after including age, sex, dose, and length of treatment in the models. Lithium was rated higher than valproate and quetiapine, although this difference did not reach statistical significance. Obsessive-compulsive symptoms, emotional hyperreactivity, cognitive symptoms, anxiety, weight gain, and gastrointestinal symptoms emerged as significant predictors of treatment dissatisfaction.

The findings of this study underscore the significant role that emotional and psychological side effects play in treatment dissatisfaction during MSA use. Both research and clinical decisions should consider the subjective experiences of patients undergoing MSA treatment.